title: Effect of continuous venovenous hemodiafiltration on darunavir and raltegravir exposure after administration via a gastroduodenal tube.
authors.forename: Anne B
authors.initials: AB
authors.lastname: Taegtmeyer
authors.forename: Veronique
authors.initials: V
authors.lastname: Müller
authors.forename: Helen
authors.initials: H
authors.lastname: Kovari
authors.forename: Gerd A
authors.initials: GA
authors.lastname: Kullak-Ublick
authors.forename: Natascia
authors.initials: N
authors.lastname: Corti
mesh_terms: D000328:Adult; D044966:Anti-Retroviral Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D000069454:Darunavir; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D017583:Hemodiafiltration / Q000379:methods*; D006801:Humans; D008297:Male; D011760:Pyrrolidinones / Q000008:administration & dosage* / Q000493:pharmacokinetics; D000068898:Raltegravir Potassium; D013449:Sulfonamides / Q000008:administration & dosage* / Q000493:pharmacokinetics; D016896:Treatment Outcome
chemical_list: D044966:Anti-Retroviral Agents; D011760:Pyrrolidinones; D013449:Sulfonamides; D000068898:Raltegravir Potassium; D000069454:Darunavir